PMID- 22971679
OWN - NLM
STAT- MEDLINE
DCOM- 20130322
LR  - 20240322
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 41
IP  - 5
DP  - 2012 Nov
TI  - Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in 
      patients with hepatocellular carcinoma.
PG  - 1601-9
LID - 10.3892/ijo.2012.1626 [doi]
AB  - Dendritic cells (DCs) are increasingly used as adjuvants for vaccination 
      strategies; however, there has been very little development in DC vaccines for 
      patients with hepatocellular carcinoma (HCC). In this study, we assessed the 
      safety, feasibility and efficacy of a multiple tumor-associated antigen 
      (TAA)-pulsed DC vaccine in 5 patients with advanced HCC. DCs were generated by 
      culturing blood monocytes in the presence of granulocyte macrophage-colony 
      stimulating factor and interleukin-4 for 5 days. The DC vaccine was prepared by 
      pulsing DCs with cytoplasmic transduction peptide-attached alpha-fetoprotein, 
      glypican-3 and MAGE-1 recombinant fusion proteins and cultivating them in the 
      presence of maturation cocktail. DCs were injected subcutaneously near the 
      inguinal lymph nodes, followed by topical application of toll-like receptor-7 
      agonist around the injection site. We showed that our DC vaccine was safe and 
      well-tolerated over 6 vaccinations in 5 patients. All 5 patients showed T cell 
      responses against TAAs. Clinical benefit was observed in one of the 5 patients. 
      In conclusion, the feasibility, safety and immune activity of DCs pulsed with 
      TAAs were confirmed in HCC patients. However, clinical response was detected only 
      in one patient. Future trials may consider applying this therapy in a less 
      advanced stage to obtain better clinical responses.
FAU - Tada, Fujimasa
AU  - Tada F
AD  - Department of Gastroenterology and Metabology, Ehime University Graduate School 
      of Medicine, To-on, Ehime 791‑0925, Japan.
FAU - Abe, Masanori
AU  - Abe M
FAU - Hirooka, Masashi
AU  - Hirooka M
FAU - Ikeda, Yoshiou
AU  - Ikeda Y
FAU - Hiasa, Yoichi
AU  - Hiasa Y
FAU - Lee, Yoon
AU  - Lee Y
FAU - Jung, Nam-Chul
AU  - Jung NC
FAU - Lee, Woo-Bok
AU  - Lee WB
FAU - Lee, Hyun-Soo
AU  - Lee HS
FAU - Bae, Yong-Soo
AU  - Bae YS
FAU - Onji, Morikazu
AU  - Onji M
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120911
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Cytokines)
SB  - IM
MH  - Aged
MH  - Antigens, Neoplasm/*immunology
MH  - Cancer Vaccines/adverse effects/immunology/*therapeutic use
MH  - Carcinoma, Hepatocellular/pathology/*therapy
MH  - Cytokines/biosynthesis/immunology
MH  - Dendritic Cells/*immunology
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/pathology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - T-Lymphocytes/immunology
MH  - Treatment Outcome
PMC - PMC3583872
EDAT- 2012/09/14 06:00
MHDA- 2013/03/23 06:00
PMCR- 2012/09/11
CRDT- 2012/09/14 06:00
PHST- 2012/04/25 00:00 [received]
PHST- 2012/06/29 00:00 [accepted]
PHST- 2012/09/14 06:00 [entrez]
PHST- 2012/09/14 06:00 [pubmed]
PHST- 2013/03/23 06:00 [medline]
PHST- 2012/09/11 00:00 [pmc-release]
AID - ijo-41-05-1601 [pii]
AID - 10.3892/ijo.2012.1626 [doi]
PST - ppublish
SO  - Int J Oncol. 2012 Nov;41(5):1601-9. doi: 10.3892/ijo.2012.1626. Epub 2012 Sep 11.